<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536820</url>
  </required_header>
  <id_info>
    <org_study_id>PNIT2015</org_study_id>
    <nct_id>NCT02536820</nct_id>
  </id_info>
  <brief_title>Psychoneuroimmunology Therapy in Uncontrolled Diabetic Patients: A Quasi-experimental Study</brief_title>
  <acronym>PNIT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Salutia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coomeva E.P.S</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sinergia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Salutia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Psychoneuroimmunotherapy (PNIT) is the study, modification and implementation of the&#xD;
      interactions between the processes of adaptive behavior, neurological, endocrine and immune.&#xD;
&#xD;
      Among its premises assuming homeostasis or physiological balance as an integrated process&#xD;
      involving the systems above mentioned.&#xD;
&#xD;
      Additionally, among the basics theme the re-mean is introduced, ie changing the direction,&#xD;
      the function of a concept from a negative context carry a positive meaning, so that from the&#xD;
      PNIT no disease is seen as a problem but as a situation to solve. The patient then transmits&#xD;
      the importance of which will come.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To investigate whether patients on PNIT have a higher proportion of patients achieving&#xD;
      disease control (&lt;7% in glycosylated hemoglobin (HBAC1) and quality of life compared with&#xD;
      conventional treatment patients.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      quasi-experimental, simple blind, simple blind, parallel, phase III clinical trial The&#xD;
      investigators will follow a group of patients with type 2 diabetes mellitus durgin three&#xD;
      months with an interim analysis a month after receiving the intervention (two visits) During&#xD;
      each visit a trained PNIT physician assess the effectiveness, safety and quality of life of&#xD;
      each patient.&#xD;
&#xD;
      The investigators will include male or female patients aged 18 years-old with diabetes&#xD;
      mellitus type II in any severity, uncontrolled (&gt; 7% Glycosilated Haemoglobin (HbAc1)) and&#xD;
      any treatment regimen included.&#xD;
&#xD;
      The patients are not allocated by a random process and the investigators will have a&#xD;
      convenience sample&#xD;
&#xD;
      The investigators will perform an intention to treat analysis, patients will be analyzed&#xD;
      according to the intervention received even if this was different from the one they were&#xD;
      assigned.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycosylated hemoglobin (HbAc1 %)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (mmol/L)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life in participants in each arm</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up lost</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Conventional treatment + PNIT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PNIT: Psychoneuroimmuno therapy Conventional treatment: Usual treatment that each diabetic patient recieved</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional treatment: Usual treatment that each diabetic patient recieved</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>psychoneuroimmune therapy</intervention_name>
    <arm_group_label>Conventional treatment + PNIT</arm_group_label>
    <other_name>Solarte Technique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Actual diabetes treatment in each participant</description>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who wish to participate with informed consent sign.&#xD;
&#xD;
          -  Diagnosed with uncontrolled diabetes mellitus type II (&gt; 7% of HbAc1) at least six&#xD;
             months before starting the study&#xD;
&#xD;
          -  No change in medication at least three months before starting the study.&#xD;
&#xD;
          -  Participants with acceptable electrocardiographic results acceptable at the study&#xD;
             start.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, or planning to become pregnant during the study period.&#xD;
&#xD;
          -  History of severe liver failure.&#xD;
&#xD;
          -  Participants requiring elective surgeries or other procedures requiring general&#xD;
             anesthesia for the duration of the study.&#xD;
&#xD;
          -  Participants who are participating in other clinical trials involving drugs or who&#xD;
             have participated in another clinical trial in the last three months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>August 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

